Eastwood Bio-medical Canada Inc. (TSX-V: EBM) (the “Company”) is pleased to announce the Company has begun negotiating an export agreement with a third party company based in Asia. The contemplated deal would involve the third party purchasing unspecified volumes of five unique Eleotin® products developed for the Asian market.
The third party expressed preference for purchasing Eleotin® products company from the Company instead of Eastwood Bio-Medical Research Inc. (“EBMR”), a major shareholder of the Company. EBMR has expressed a willingness to negotiate the transfer of certain Asian distribution rights to the Company.
All agreements will be subject Exchange and Board approval as necessary.
For further information, please contact:
Eastwood Bio-medical Canada Inc.
Yunji Kim, President and Chief Executive Officer
This email contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forwardlooking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company, including expectations and assumptions concerning TSXV approvals. Although the Company believes that the expectations and assumptions on which such forwardlooking statements and information are based are reasonable, undue reliance should not be placed on the forwardlooking statements and information because the Company can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Certain factors, which could materially affect such forward-looking information are described in the risk factors in the Company’s most recent annual management’s discussion and analysis that is available on the Company’s profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forwardlooking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.